Answers are grounded in this paper and cite their sources.
Epithelial ovarian cancer is the most common type of ovarian cancer (90%) with a 5-year survival of less than 50%. Causes include genetic mutations and inflammation. Epithelial ovarian cancer mortality can be affected by age, parity, stage and histology type. Anti-Müllerian hormone is a glycoprotein belonging to TGF-β that can inhibit ovarian cancer proliferation, invasion, metastasis, and drug resistance. Immune cells that react to the presence of tumor cells will release cytokines that can cause anemia. This study aims to analyze the correlation of hemoglobin levels with preoperative serum AMH levels in epithelial ovarian cancer stages. This cross-sectional study involved 70 female patients suspected of epithelial ovarian cancer aged 40 - 79 years at Dr. Moewardi General Hospital (RSDM), Surakarta carried out from September to October 2024. Anti-Müllerian hormone levels were measured with the chemiluminescence immunoassay method (Snibe Maglumi X3), hemoglobin, neutrophils, lymphocytes, platelet were analyzed with flowcytometry method (Sysmex XN 1000) and CA 125 were analyzed with enzyme linked fluorescent assay method (Vidas Biomerieux). Correlation test using Spearman (p <0.05). There was a weak positive correlation between hemoglobin levels with AMH levels at the advanced stage (r=0.381, p=0.031). Therefore, hemoglobin levels might influence AMH levels in epithelial ovarian cancer stage.
No takes yet. Share an insight, caveat, or question.
Sari et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: